Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Status
Active
Cancer Type
Bladder Cancer
Kidney Cancer
Trial Phase
Phase II
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT02872714
Protocol IDs
INCB 54828-201 (primary)
NCI-2016-01513
Study Sponsor
Incyte Corporation

Summary

The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a

monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma

harboring FGF/FGFR alterations.

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.